457 related articles for article (PubMed ID: 24077095)
1. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
Kosoglou T; Hubbell J; Cutler DL; Johnson-Levonas AO; Xu D; Kantesaria BS; Kim K; Miller SD
Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095
[TBL] [Abstract][Full Text] [Related]
2. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.
Affrime MB; Kosoglou T; Thonoor CM; Flannery BE; Herron JM
Chest; 2000 Dec; 118(6):1538-46. PubMed ID: 11115437
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma.
Maspero JF; Nolte H; Chérrez-Ojeda I;
J Asthma; 2010 Dec; 47(10):1106-15. PubMed ID: 20874458
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.
Kosoglou T; Hubbell J; Xuan F; Cutler DL; Meehan AG; Kantesaria B; Wittmer BA
Int J Chron Obstruct Pulmon Dis; 2013; 8():107-16. PubMed ID: 23525511
[TBL] [Abstract][Full Text] [Related]
5. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects.
Chrousos GP; Ghaly L; Shedden A; Iezzoni DG; Harris AG
Chest; 2005 Jul; 128(1):70-7. PubMed ID: 16002918
[TBL] [Abstract][Full Text] [Related]
6. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
Daley-Yates PT; Deans A; Mehta R; Sousa AR
Pulm Pharmacol Ther; 2022 Dec; 77():102171. PubMed ID: 36243386
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma.
Nolte H; Pavord I; Backer V; Spector S; Shekar T; Gates D; Nair P; Hargreave F
Respir Med; 2013 May; 107(5):656-64. PubMed ID: 23490226
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device.
Kosoglou T; Hubbell J; Johnson-Levonas AO; Yunan M; Kantesaria BS; Cutler DL
Clin Pharmacol Drug Dev; 2014 May; 3(3):222-8. PubMed ID: 27128612
[TBL] [Abstract][Full Text] [Related]
10. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
[TBL] [Abstract][Full Text] [Related]
11. Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma.
Maspero J; Cherrez I; Doherty DE; Tashkin DP; Kuna P; Kuo WL; Gates D; Nolte H; Chylack LT
Respir Med; 2014 Sep; 108(9):1355-62. PubMed ID: 25044280
[TBL] [Abstract][Full Text] [Related]
12. Comparing the efficacy and safety of salmeterol/fluticasone pMDI versus its mono-components, other LABA/ICS pMDIs and salmeterol/fluticasone Diskus in patients with asthma.
Mehta N; Aggarwal B; Gogtay J; Abdool-Gaffar S
Expert Opin Drug Deliv; 2015 Jun; 12(6):963-75. PubMed ID: 25429610
[TBL] [Abstract][Full Text] [Related]
13. Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function.
Lee DK; Bates CE; Currie GP; Cowan LM; McFarlane LC; Lipworth BJ
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):253-8. PubMed ID: 15478385
[TBL] [Abstract][Full Text] [Related]
14. Bronchodilation with mometasone furoate/formoterol fumarate administered by metered-dose inhaler with and without a spacer in children with persistent asthma.
Berger WE; Bensch GW; Weinstein SF; Skoner DP; Prenner BM; Shekar T; Nolte H; Teper AA
Pediatr Pulmonol; 2014 May; 49(5):441-50. PubMed ID: 24019197
[TBL] [Abstract][Full Text] [Related]
15. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study.
Bodzenta-Lukaszyk A; Dymek A; McAulay K; Mansikka H
BMC Pulm Med; 2011 May; 11():28. PubMed ID: 21605396
[TBL] [Abstract][Full Text] [Related]
16. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma.
Skoner DP; Meltzer EO; Milgrom H; Stryszak P; Teper A; Staudinger H
J Asthma; 2011 Oct; 48(8):848-59. PubMed ID: 21854342
[TBL] [Abstract][Full Text] [Related]
17. Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis.
Kosoglou T; Cutler DL; Staudinger H; Herron JM
Chest; 2010 Jan; 137(1):115-21. PubMed ID: 19749003
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Gates D; Staudinger H
Int J Chron Obstruct Pulmon Dis; 2012; 7():73-86. PubMed ID: 22334770
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.
Kosoglou T; Hubbell J; Kantesaria B; Hanson ME; Cutler DL
Clin Pharmacol Drug Dev; 2014 May; 3(3):229-34. PubMed ID: 27128613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
